Parabilis Medicines, Inc. (NASDAQ:PBLS) Stock Has Consensus Target Price of $41.67 According to Analysts

Shares of Parabilis Medicines, Inc. (NASDAQ:PBLS) have been assigned a consensus recommendation of “Moderate Buy” from the seven research firms that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, four have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $41.67.

Several analysts recently weighed in on PBLS shares. Guggenheim assumed coverage on Parabilis Medicines in a report on Monday, July 6th. They set a “buy” rating and a $40.00 price target on the stock. Bank of America initiated coverage on shares of Parabilis Medicines in a report on Monday, July 6th. They set a “buy” rating and a $45.00 price target on the stock. Evercore initiated coverage on Parabilis Medicines in a research note on Monday, July 6th. They issued an “outperform” rating on the stock. Weiss Ratings raised shares of Parabilis Medicines from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday, October 16th. Finally, Leerink Partners started coverage on shares of Parabilis Medicines in a research report on Monday, July 6th. They set an “outperform” rating and a $40.00 target price on the stock.

Parabilis Medicines Stock Performance

NASDAQ PBLS opened at $27.85 on Thursday. Parabilis Medicines has a 52 week low of $22.66 and a 52 week high of $42.49. The stock has a 50-day moving average of $34.61.

Parabilis Medicines (NASDAQ:PBLS) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($2.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($2.16). The business had revenue of $0.15 million for the quarter. On average, equities analysts predict that Parabilis Medicines will post -3.09 EPS for the current fiscal year.

Hedge Funds Weigh In On Parabilis Medicines

A number of institutional investors have recently bought and sold shares of PBLS. Persistent Asset Partners Ltd acquired a new position in Parabilis Medicines during the second quarter valued at $113,000. Alyeska Investment Group L.P. acquired a new stake in shares of Parabilis Medicines during the 2nd quarter valued at about $274,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in Parabilis Medicines in the second quarter valued at approximately $526,000. WINTON GROUP Ltd purchased a new position in shares of Parabilis Medicines during the 2nd quarter valued at approximately $955,000. Finally, Squarepoint Ops LLC purchased a new position in shares of Parabilis Medicines during the 2nd quarter valued at approximately $1,327,000.

About Parabilis Medicines

Parabilis Medicines Inc is a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease. Parabilis Medicines Inc is based in CAMBRIDGE, Mass.